GI Dynamics has designated the Epworth Centre for Bariatric Surgery (www.obesity.com.au) in Victoria as the first center of excellence for the EndoBarrier Gastrointestinal Liner (www.endobarrier.com) in Australia. It is expected that the first EndoBarrier patients in Australia will undergo treatment in the first half of this year.
The EndoBarrier, which received approval from the Therapeutic Goods Administration last year for sale in Australia, is a thin, flexible, tube-shaped liner that forms a physical barrier between food and part of the wall of the intestine. It has been clinically proven to lower HbA1c levels, achieve weight loss by more than 20%, and improve other important metabolic functions, including cholesterol, blood pressure, and triglycerides, all of which contribute to the severity of type 2 diabetes.1
The EndoBarrier is currently available in select markets in Europe and in Chile. A hospital is chosen to be a center of excellence based on its expertise in the treatment and management of Type 2 diabetes and obesity and its support programs for patients undergoing treatment for these conditions. Clinical studies involving more than 500 patients have demonstrated that the EndoBarrier can help people living with Type 2 diabetes and obesity achieve blood sugar control and significant weight loss.
1 C. de Jonge, J.W. Greve, N, Bouvy, et al., EndoBarrier Gastrointestinal Liner treatment rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients, Department of Surgery, Maastricht University Medical Centre, presented at IFSO 2011, Hamburg, Germany.
iConnectHub
Access
Login/Register
Supplier Login
